March 25 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA'S IL-2 SUPERKINE, MDNA19, DEMONSTRATES BEST-IN-CLASS FEATURES IN A NON-HUMAN PRIMATE STUDY
* MEDICENNA - KINETIC STUDIES IN NHP SHOWED DOSE-DEPENDENT UPREGULATION OF KI67 IN CD8 T-CELLS LASTING FOR ALMOST 2 WEEKS POST-MDNA19 ADMINISTRATION
* MEDICENNA THERAPEUTICS CORP - SUCCESSFULLY CLOSED A $35 MILLION FINANCING LAST WEEK